| Name | N-Benzylglycylglycylglycyl-L-phenylalanyl-L-threonylglycyl-L-alanyl-L-arginyl-L-lysyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-arginyl-L-lysyl-L-asparaginyl-L-glutamamide |
|---|---|
| Synonyms |
[NPHE1, G14, LYS15]NOCICTIN-NH2
L-Glutamamide, N-(phenylmethyl)glycylglycylglycyl-L-phenylalanyl-L-threonylglycyl-L-alanyl-L-ginyl-L-lysyl-L-seryl-L-alanyl-L-ginyl-L-lysyl-L-ginyl-L-lysyl-L-aspaginyl- (9CI) N-(BZL)GLY-GLY-GLY-PHE-THR-GLY-ALA-G-LYS-SER-ALA-G-LYS-G-LYS-ASN-GLN-NH2 PubChem ID N-(Bzl)Gly-Gly-Gly-Phe-Thr-Gly-Ala-g-Lys-Ser-Ala-g-Lys-g-Lys-Asn-Gln-NH2 (N-(Bzl)GlyN-Benzylglycine) |
| Description | UFP-101 is a potent, selective, and competitive antagonist of the nociceptin/orphanin FQ (NOP) receptor, with a pKi of 10.24. UFP-101 displays >3000-fold selectivity over δ, μ and κ opioid receptors. UFP-101 shows antidepressant-like effect[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | UFP-101 elicits a pronounced acute and dosedependent antidepressant-like effect in mice submitted to the forced swimming test (FST)[1]. |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Molecular Formula | C82H138N32O21 |
| Molecular Weight | 1908.175 |
| Exact Mass | 1907.071411 |
| LogP | -10.03 |
| Index of Refraction | 1.668 |